HANGZHOU TIGERMED CONSULTING (300347) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 Apr, 2026Executive summary
Revenue for Q1 2026 reached ¥1.80 billion, up 15.17% year-over-year, while net profit attributable to shareholders dropped 70.36% to ¥49.04 million.
Net profit excluding non-recurring items rose 17.65% year-over-year to ¥120.39 million.
Operating cash flow increased 60.51% year-over-year to ¥317.70 million.
Financial highlights
Total assets at quarter-end were ¥28.80 billion, up 1.56% from year-end 2025.
Shareholders’ equity was ¥20.92 billion, down 0.21% from year-end 2025.
Basic and diluted EPS were both ¥0.06, down 68.42% year-over-year.
Weighted average ROE was 0.23%, down 0.57 percentage points year-over-year.
Outlook and guidance
No explicit forward-looking guidance provided, but management commentary highlights increased government support and investment returns.
Latest events from HANGZHOU TIGERMED CONSULTING
- Revenue up 3.5% YoY, net profit attributable to owners up 119.2%, global expansion and digitalization advanced.300347
H2 20251 May 2026 - Q3 revenue and profit declined sharply year-over-year, despite a major acquisition.300347Q3 202424 Dec 2025
- Revenue and profit fell, but global expansion and stable margins support long-term growth.300347H1 202424 Dec 2025
- Net profit plunged 79.99% on lower revenue and margin, but global expansion continued.300347H2 202424 Dec 2025
- H1 2025 saw lower profit and margin, but overseas growth and cash flow improved.300347H1 202524 Dec 2025
- Q3 net profit surged 98.73% year-over-year, mainly from investment and fair value gains.300347Q3 202528 Oct 2025
- Revenue and profit fell, but new contracts and cash flow showed strong growth in Q1 2025.300347Q1 20256 Jun 2025